



Dr. med. Gregory Wirth

Urologie opératoire, Urologie

Sprachen

FR,DE,EN

Mitgliedschaften

- Associations suisse (SSU), européenne (EAU) et américaine (AUA) d'urologie
- AMGe
- FMH
- SAKK (Groupe suisse de recherche clinique sur le cancer)
- Société de médecine du canton de Fribourg (SMCF)

Ausbildung

2019	DKG (Deutsche Krebsgesellschaft) expert in prostate cancer
2017	Main focus on urological surgery
2015-2016	Fellowship in urological oncology, Allgemeines Krankenhaus der Stadt Wien, Austria (AKH Wien) / Medical University of Vienna.
2014	FMH certification in urology
2010-2011	Fellowship at Massachusetts General Hospital / Harvard Medical School, Boston, USA (scholarship from the Ligue Suisse pour la Recherche contre le Cancer)
2004	Doctoral thesis
1997-2004	Faculty of medicine, University of Freiburg

Berufserfahrung

2020	Independent urologist, Urology centre, Clinique Générale-Beaulieu (Geneva) and Cabinet Fleury & Wirth (Fribourg) Attending physician, Urology department, Hôpitaux Universitaires de Genève
2015-2020	Acting Chief medical officer, Hôpitaux Universitaires de Genève
2014-2020	Co-founder and coordinator of the Prostate cancer centre of the Hôpitaux Universitaires de Genève
2012-2015	Full-time Chief resident, Urology department, Hôpitaux Universitaires de Genève
2011-2012	Full-time Resident, Urology department, Hôpitaux Universitaires de Genève
2007-2010	Full-time Resident, Urology department, Hôpitaux Universitaires de Genève (Prof. Iselin)
2004-2007	Full-time Resident, Surgery department rotation, Hôpitaux Universitaires de Genève (Prof. Morel)

Publikationen

1. Wu S, Xie L, Lin S, Wirth GJ, Lu M, Zhang Y, Blute M, Dahl DM, Wu C. Quantification of perineural invasion focus after radical prostatectomy could improve predictive power of recurrence. *Hum Pathol.* 2020 Jul 13; 104:96-104.
2. Rentsch CA, Bosshard P, Mayor G, Rieken M, Püschel H, Wirth G, Cathomas R, Parzmair GP, Grode L, Eisele B, Sharma H, Gupta M, Gairola S, Shaligram U, Goldenberger D, Spertini F, Audran R, Enoiu M, Berardi S, Hayoz S, Wicki A. Results of the phase I open label clinical trial SAKK 06/14 assessing safety of intravesical instillation of VPM1002BC, a recombinant mycobacterium *Bacillus Calmette Guérin* (BCG), in patients with non-muscle invasive bladder cancer and previous failure of conventional BCG therapy. *Oncoimmunology* 2020 Apr 21;9(1):1748981.
3. Wu S, Lin SX, Wirth GJ, Lu M, Lu J, Subtelny AO, Wang Z, Dahl DM, Olumi AF, Wu CL. Impact of Multifocality and Multilocation of Positive Surgical Margin After Radical Prostatectomy on Predicting Oncological Outcome. *Clin Genitourin Cancer.* 2019 Feb;17(1):e44-e52.
4. Mordasini L, Di Bona C, Klein J, Mattei A, Wirth G, Iselin CE. 80-W GreenLight Laser Vaporization Versus Transurethral Resection of the Prostate for Treatment of Benign Prostatic Obstruction: 5-Year Outcomes of a Single-Center Prospective Randomized Trial. *Urology.* 2018 Feb 12; S0090-4295(18)30094-3. Impact Factor 2.3
5. Benamran DA, Klein J, Hadaya K, Wirth GJ, Martin PY, Iselin CE. Post-kidney Transplant Robot-assisted Laparoscopic Ureteral (Donor-receiver) Anastomosis for Kidney Graft Reflux or Stricture Disease. *Urology.* 2017 Oct; 108:96-101. Impact Factor 2.3
6. Soria F, Moschini M, Wirth GJ, Gust KM, Klatte T, Briganti A, Gontero P, Abufaraj M, Özsoy M, Karakiewicz PI, Shariat SF. Characterization of Late Recurrence After Radical Cystectomy in a Large Multicenter Cohort of Bladder Cancer Patients. *Urology.* 2017 Aug; 106:119-124. Impact Factor 2.3
7. Fenner V, Benamran DA, Tran SN, Venzi G, Wirth GJ, Iselin CE. Bulbomembranous anastomotic urethroplasty for strictures of the proximal bulbar urethra unassociated with pelvic trauma. *Int J Urol.* 2017 Jul;24(7):556-558. doi: 10.1111/iju.13347 Impact factor 1.844
8. Soria F, Moschini M, Abufaraj M, Wirth GJ, Foerster B, Gust KM, Özsoy M, Briganti A, Gontero P, Mathieu R, Rouprêt M, Karakiewicz PI, Shariat SF. Genève, le 29.09.2020
Preoperative anemia is associated with disease recurrence and progression in patients with non-muscle-invasive bladder cancer. *Urol Oncol.* 2017 Mar;35(3):113.e9-113.e14. Impact factor 3.767
9. Klein J, de Gorski A, Benamran D, Vallee JP, De Perrot T, Wirth GJ, Iselin CE. Transrectal Ultrasound-Guided Prostate Biopsy for Cancer Detection: Performance of 2D-, 3D- and 3D-MRI Fusion Targeted Techniques. *Urol Int.* 2016 Oct 27 Impact factor 1.611
10. Wirth GJ, Haitel A, Moschini M, Soria F, Klatte T, Hassler MR, Bensalah K, Briganti A, Karam JA, Lotan Y, Margulis V, Raman JD, Remzi M, Rioux-Leclercq N, Robinson BD, Rouprêt M, Wood CG, Shariat SF. Androgen receptor expression is associated with adverse pathological features in ureteral but not in pelvicalyceal urothelial carcinomas of the upper urinary tract. *World J Urol.* 2016 Oct 11 Impact factor 2.743

11. Soria F, Moschini M, Haitel A, Wirth GJ, Gust KM, Briganti A, Rouprêt M, Klatte T, Hassler MR, Karakiewicz PI, Shariat SF. The effect of HER2 status on oncological outcomes of patients with invasive bladder cancer. *Urol Oncol*. 2016 Dec;34(12):533.e1-533.e10. Impact factor 3.767

12. Moschini M, Soria F, Klatte T, Wirth GJ, Özsoy M, Gust K, Briganti A, Rouporet M, Susani M, Haitel A, Shariat SF. Validation of Preoperative Risk Grouping of the Selection of Patients Most Likely to Benefit From Neoadjuvant Chemotherapy Before Radical Cystectomy. *Clin Genitourin Cancer*. 2016 Jul 22. Impact factor 2.535

13. Soria F, Moschini M, Haitel A, Wirth GJ, Karam JA, Wood CG, Rouprêt M, Margulis V, Karakiewicz PI, Briganti A, Raman JD, Kammerer-Jacquet SF, Mathieu R, Bensalah K, Lotan Y, Özsoy M, Remzi M, Gust KM, Shariat SF. HER2 overexpression is associated with worse outcomes in patients with upper tract urothelial carcinoma (UTUC). *World J Urol*. 2016 Jun 7. Impact factor 2.743

14. Bamias A, Tsantoulis P, Zilli T, Papatsoris A, Caparrotti F, Kyratsas C, Tzannis K, Stravodimos K, Chrisofos M, Wirth GJ, Skolarikos A, Mitropoulos D, Constantinides CA, Deliveliotis C, Iselin CE, Miralbell R, Dietrich PY, Dimopoulos MA. Outcome of patients with nonmetastatic muscle-invasive bladder cancer not undergoing cystectomy after treatment with noncisplatin-based chemotherapy and/or radiotherapy: a retrospective analysis. *Cancer Med*. 2016 Jun;5(6):1098-107 Impact factor 3.362

15. Di Pierro GB, Grande P, Wirth JG, Danuser H, Mattei A. Extended pelvic lymph node dissection at the time of robot-assisted radical prostatectomy: Impact of surgical volume on efficacy and complications in a single-surgeon series. *Can Urol Assoc J*. 2015 Mar-Apr;9(3-4):107-13. Genève, le 29.09.2020

16. Tran SN, Wirth GJ, Mayor G, Rollini C, Bianchi-Demicheli F, Iselin CE. Prospective evaluation of early postoperative male and female sexual function after radical prostatectomy with erectile nerves preservation. *Int J Impot Res*. 2015 Jan 15. doi: 10.1038/ijir.2014.36. impact factor 1.293

17. Di Pierro GB, Wirth JG, Ferrari M, Danuser H, Mattei A. Impact of a single-surgeon learning curve on complications, positioning injuries, and renal function in patients undergoing robot-assisted radical prostatectomy and extended pelvic lymph node dissection. *Urology*. 2014 Nov;84(5):1106-11. doi: 10.1016/j.urology.2014.06.047. Impact Factor 2.3

18. Retèl PV, Bouchardy C, Usel M, Neyroud-Caspar I, Schmidlin F, Wirth G, Iselin C, Miralbell R, Rapiti E. Determinants and effects of positive surgical margins after prostatectomy on prostate cancer mortality: a population-based study. *BMC Urology* 2014 Nov 5;14:86. Impact factor 1.720

19. Fendt SM, Bell EL, Keibler MA, Davidson SM, Wirth GJ, Fiske B, Mayers J, Blouin MJ, Bellinger G, Csibi A, Cantley LC, Patnaik A, Guarente LP, Blenis J, Pollak M, Schwab M, Olumi AF, Vander Heiden MG, Stephanopoulos G. Metformin decreases glucose oxidation and increases the dependency of prostate cancer cells on reductive glutamine metabolism. *Cancer Research*, 2013 Jul 15;73(14):4429-38. Impact factor 9.122

20. Wirth GJ, Psutka SP, Chapin BF, Wu S, Wu C-L, Dahl DM. Midterm oncologic outcomes of laparoscopic versus open radical prostatectomy. *BJU Int*. 2013 Jul;112(2):190-7. Impact factor 4.338 (Editor's Choice)

21. Lu J & Wirth GJ (shared first authorship), Wu S, Chen J, Dahl DM, Olumi AF, Young RH, McDougal WS, Wu CL
A Close Surgical Margin After Radical Prostatectomy is an Independent Predictor of Recurrence.
Journal of Urology 2012 Jul;188(1):91-7. impact factor 5.157
22. Wirth GJ, Poletti PA, Peter R, Iselin CE
Advances in the management of blunt traumatic bladder ruptures: experience with 36 cases.
BJU Int. 2010 Nov;106(9):1344-9. Impact factor 4.338
23. Smith V, Wirth GJ, Fiebig HH, Burger AM
Tissue microarrays of human tumor xenografts: characterization of proteins involved in migration and angiogenesis for applications in the development of targeted anticancer agents.
Cancer Genomics Proteomics. 2008 Sep-Oct;5(5):263-73. Impact factor 1.892
Genève, le 29.09.2020
24. Wirth GJ, Schandelmaier K, Smith V, Burger AM, Fiebig HH.
Microarrays of 41 human tumor cell lines for the characterization of new molecular targets: expression patterns of cathepsin B and the transferrin receptor.
Oncology. 2006;71(1-2):86-94. Impact factor 2.262
25. Wirth GJ, Teuscher J, Graf JD, Iselin CE.
Efavirenz-induced urolithiasis.
Urol Res. 2006 Aug;34(4):288-9. (journal renommé "Urolithiasis") Impact factor 1.8
26. Feutry G, De Perrot T, Wirth GJ, Montet X, Martin SP.
Prostatic Utricle Cyst as the Most Likely Cause in a Case of Recurrent Episodes of Hematospermia.
Case Rep Urol. 2017;2017: 7502878
27. Mayor G, Wirth GJ, Sanchez-Pareja A, La harpe R, Gehrig C, Iselin CE.
De novo undifferentiated pleomorphic sarcoma arising from a renal allograft.
Cancer Treatment Comm. 2015 (3):17-20 impact factor ?

Akkreditierung

[Clinique Générale-Beaulieu](#)

Fachgebiete

[Urologie](#)

[Prostatakrebs \(Prostatakarzinom\)](#)

[Da Vinci](#)

Kontakt

Centre d'Urologie Générale-Beaulieu

Chemin de Beau-Soleil 12
1206 Genève

T +41 22 347 47 15

dr.gw@hin.ch

<https://www.swissmedical.net/fr/hopitaux/generale-beaulieu/centres/urologie>

[vCard herunterladen](#)